RFK Jr.'s CDC vaccine panel backs Merck RSV shot for infants

The Advisory Committee on Immunization Practices (ACIP) unanimously recommended Merck's RSV shot, Enflonsia, for infants, ensuring its inclusion in widely covered childhood immunizations and enabling market launch ahead of the RSV season. This decision provides significant market access for Merck, positioning Enflonsia to compete with Sanofi/AstraZeneca's Beyfortus in a critical pediatric health segment. The vote offers a notable reprieve for drugmakers and public health officials, particularly given recent controversial appointments to the advisory panel, despite some dissenting votes from new members.

Analysis

The U.S. Advisory Committee on Immunization Practices (ACIP) has recommended Merck's respiratory syncytial virus (RSV) shot, Enflonsia, for infants, a pivotal development that de-risks its commercial launch. This decision secures its inclusion in the government's recommended childhood immunization list, ensuring broad insurance coverage and clearing the path for market entry ahead of the upcoming RSV season. The vote provides a significant reprieve for Merck and the broader pharmaceutical industry, as it occurred despite recent controversial appointments of vaccine critics to the panel, signaling that strong clinical data can overcome potential political hurdles. Enflonsia's trial data is compelling, demonstrating an 84% reduction in RSV-related hospitalizations and a 90% decrease in hospitalizations from related lower respiratory infections. This positions the product as a strong head-to-head competitor against the established rival shot, Beyfortus, from Sanofi and AstraZeneca. With both being monoclonal antibodies targeting different viral components, the competitive landscape will likely be defined by marketing, distribution, and real-world evidence rather than direct efficacy comparisons.

Key Decisions for Investors

• The ACIP recommendation is a material positive catalyst for Merck (MRK), significantly improving the commercial outlook for Enflonsia and validating a key asset in its vaccine pipeline.
• Investors should now closely monitor the market dynamics between Merck's Enflonsia and the Sanofi/AstraZeneca offering, focusing on initial uptake, pricing strategies, and physician adoption as key performance indicators.
• While the approval is a clear win, the noted dissent from two panel members introduces a political risk factor, suggesting that future vaccine-related regulatory decisions could face increased scrutiny, a trend to watch across the sector.